Autopsy report · NCT02812030

Aflibercept for Retinopathy in the Real World

“Superceded by a larger trial by the pharmaceutical company”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Timothy Jones

Sponsor type

University, hospital or other

Conditions

Diabetic Retinopathy

Interventions

National Eye Institute Visual Functioning Questionnaire

Participants

0

Trials that died the same way

• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
  “Pharmaceutical company pulled support for the trial.” (71% match in meaning)
• A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
  “The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been approved).The sponsor terminated the trial.” (65% match in meaning)
• CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
  “Termination by pharmaceutical sponsor” (64% match in meaning)
• A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
  “The trial was stopped early due to insufficient study drug supply and study funding constraints” (62% match in meaning)
• Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
  “Termination of the clinical trial by sponsor.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.